Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers

Advances in Therapy

Volumn 29, Issue 10, 2012, Pages 889-899

  Brand, Tobias ^a   MacHa, Sreeraj ^b   Mattheus, Michaela ^a   Pinnetti, Sabine ^a   Woerle, Hans J ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

BI 10773; Diabetes; Dipeptidyl peptidase 4 inhibitor; Drug drug interaction; Empagliflozin; Sitagliptin; Sodium glucose cotransporter 2 inhibitor

Indexed keywords

EMPAGLIFLOZIN; SITAGLIPTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; GLOSSODYNIA; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; CROSS-OVER STUDIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG INTERACTIONS; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PYRAZINES; SODIUM-GLUCOSE TRANSPORTER 2; TRIAZOLES;

EID: 84872111344     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0055-3     Document Type: Article

References (19)

1. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24:382-91.
2. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32:63-71.
3. Kipnes M. Sodium-glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials. Clin Investig. 2011;1:145-56.
4. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83-90.
5. Port A, Macha S, Seman L, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773, a sodium glucose cotransporter-2 (SGLT-2), in healthy volunteers. Diabetes. 2010;59(Suppl. 1):A155.
6. Seman L, Macha S, Jones P, et al. Safety and tolerability of BI 10773, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, following 8-days treatment in patients with type 2 diabetes. Diabetes. 2010;59(Suppl. 1):A156.
7. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan- 2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:141-51.
8. Januvia (sitagliptin) [package insert]. 2010; Merck & Co, Inc. Whitehouse Station, NJ, USA.
9. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60:470-512.
10. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28:55-72.
11. Herman GA, Stevens C, Van DK, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78:675-88.
12. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122:443-53.
13. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-59.
14. MedDRA Introductory Guide. 12th ed. Chantilly, VA: MedDRA Maintenance and Support Services Organization; 2009.
15. Gallwitz B. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc). 2007;43:13-25.
16. Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs. 2010;70:2089-112.
17. Kania DS, Gonzalvo JD, Weber ZA. Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. Clin Ther. 2011;33:1005-22.
18. Scott LJ. Linagliptin: in type 2 diabetes mellitus. Drugs. 2011;71:611-24.
19. Friedrich C, Metzmann K, Rose P, Mattheus M, Pinnetti S, Woerle H-J. Pharmacokinetics and pharmacodynamics of BI 10773, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, following co-administration in healthy volunteers. Diabetes. 2011;60(Suppl. 1):A616-7.